Sequoia Capital China led a CNY300m (~USD43.5m) Series A for BoomRay Pharmaceuticals, a China-based radioactive molecular imaging and nuclear drug transformation platform, with participation from River Head Capital, Tianfu Sanjiang Asset Management, Puhua Capital, CTS Capital, Shengmingyuan Venture Capital and Shenzhen Jincheng. Read more here and here